REFERENCES

1. Savarese G, Lund LH. Division of Cardiology. Global public health burden of heart failure. Card Fail Rev 2017;3:7.

2. Liu YW, Chen B, Yang X, et al. Human embryonic stem cell-derived cardiomyocytes restore function in infarcted hearts of non-human primates. Nat Biotechnol 2018;36:597-605.

3. Borow KM, Yaroshinsky A, Greenberg B, Perin EC. Phase 3 DREAM-HF trial of mesenchymal precursor cells in chronic heart failure. Circ Res 2019;125:265-81.

4. Sun X, Wu J, Qiang B, et al. Transplanted microvessels improve pluripotent stem cell-derived cardiomyocyte engraftment and cardiac function after infarction in rats. Sci Transl Med 2020;12:eaax2992.

5. Bolli R, Mitrani RD, Hare JM, et al. Cardiovascular Cell Therapy Research Network (CCTRN). A phase II study of autologous mesenchymal stromal cells and c-kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRN CONCERT-HF trial. Eur J Heart Fail 2021;23:661-74.

6. Leor J, Amsalem Y, Cohen S. Cells, scaffolds, and molecules for myocardial tissue engineering. Pharmacol Ther 2005;105:151-63.

7. Thai HM, Juneman E, Lancaster J, et al. Implantation of a three-dimensional fibroblast matrix improves left ventricular function and blood flow after acute myocardial infarction. Cell Transplant 2009;18:283-95.

8. Lancaster J, Juneman E, Hagerty T, et al. Viable fibroblast matrix patch induces angiogenesis and increases myocardial blood flow in heart failure after myocardial infarction. Tissue Eng Part A 2010;16:3065-73.

9. Lancaster JJ, Juneman E, Arnce SA, et al. An electrically coupled tissue-engineered cardiomyocyte scaffold improves cardiac function in rats with chronic heart failure. J Heart Lung Transplant 2014;33:438-45.

10. Gao L, Kupfer ME, Jung JP, et al. Myocardial tissue engineering with cells derived from human-induced pluripotent stem cells and a native-like, high-resolution, 3-dimensionally printed scaffold. Circ Res 2017;120:1318-25.

11. Wnorowski A, Wu JC. 3-dimensionally printed, native-like scaffolds for myocardial tissue engineering. Circ Res 2017;120:1224-6.

12. Menasché P, Vanneaux V, Hagège A, et al. Transplantation of human embryonic stem cell-derived cardiovascular progenitors for severe ischemic left ventricular dysfunction. J Am Coll Cardiol 2018;71:429-38.

13. Kawamura M, Miyagawa S, Miki K, et al. Feasibility, safety, and therapeutic efficacy of human induced pluripotent stem cell-derived cardiomyocyte sheets in a porcine ischemic cardiomyopathy model. Circulation 2012;126:S29-37.

14. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006;126:663-76.

15. Gaballa MA, Sunkomat JN, Thai H, Morkin E, Ewy G, Goldman S. Grafting an acellular 3-dimensional collagen scaffold onto a non-transmural infarcted myocardium induces neo-angiogenesis and reduces cardiac remodeling. J Heart Lung Transplant 2006;25:946-54.

16. Lancaster JJ, Sanchez P, Repetti GG, et al. Human induced pluripotent stem cell-derived cardiomyocyte patch in rats with heart failure. Ann Thorac Surg 2019;108:1169-77.

17. Sanchez P, Lancaster JJ, Weigand K, Mohran SE, Goldman S, Juneman E. Doppler assessment of diastolic function reflect the severity of injury in rats with chronic Heart failure. J Card Fail 2017;23:753-61.

18. Chinyere IR, Bradley P, Uhlorn J, et al. Epicardially placed bioengineered cardiomyocyte xenograft in immune-competent rat model of heart failure. Stem Cells Int 2021;2021:9935679.

19. Lancaster JJ, Koevary JW, Chinyere IR, Daugherty SL, Fox KA, Goldman S. Surgical treatment for heart failure: cell-based therapy with engineered tissue. Vessel Plus 2019;3:34.

20. Menasché P. Skeletal myoblasts as a therapeutic agent. Prog Cardiovasc Dis 2007;50:7-17.

21. Rajagopalan P, Shen CJ, Berthiaume F, Tilles AW, Toner M, Yarmush ML. Polyelectrolyte nano-scaffolds for the design of layered cellular architectures. Tissue Eng 2006;12:1553-63.

22. Ceccaldi C, Bushkalova R, Alfarano C, et al. Evaluation of polyelectrolyte complex-based scaffolds for mesenchymal stem cell therapy in cardiac ischemia treatment. Acta Biomater 2014;10:901-11.

23. Bushkalova R, Farno M, Tenailleau C, et al. Alginate-chitosan PEC scaffolds: a useful tool for soft tissues cell therapy. Int J Pharm 2019;571:118692.

24. Morris C, Ref JR, Acharya T Johnson KJ, et al. Free-breathing gradient recalled echo-based CMR in a swine heart failure model. Sci Rep 2022;12:3698.

25. Soukup CR, Schmidt CW, Chan-Tram C, Garberich RF, Sun BC, Traverse JH. Rate of Incomplete revascularization following coronary artery bypass grafting at a single institution between 2007 and 2017. Am J Cardiol 2021;144:33-6.

26. Pfeffer JM, Pfeffer MA, Braunwald E. Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res 1985;57:84-95.

27. Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.

28. Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE investigators. N Engl J Med 1992;327:669-77.

29. Mann DL. Use of ejection fraction in heart failure: a tarnished gold standard? Journal of the American College of Cardiology - ACCEL Audio Journal 2019. Available from: https://www.acc.org/Education-and-Meetings/Products-and-Resources/ACCEL-Audio [Last accessed on 20 Apr 2022].

30. Kerkhof PL. Characterizing heart failure in the ventricular volume domain. Clin Med Insights Cardiol 2015;9:11-31.

31. Gaasch WH, Zile MR. Left ventricular structural remodeling in health and disease: with special emphasis on volume, mass, and geometry. J Am Coll Cardiol 2011;58:1733-40.

32. Cao J, Poss KD. The epicardium as a hub for heart regeneration. Nat Rev Cardiol 2018;15:631-47.

33. Wei K, Serpooshan V, Hurtado C, et al. Epicardial FSTL1 reconstitution regenerates the adult mammalian heart. Nature 2015;525:479-85.

34. Tyser RCV, Ibarra-Soria X, McDole K, et al. Characterization of a common progenitor pool of the epicardium and myocardium. Science 2021;371:eabb2986.

35. Vagnozzi RJ, Maillet M, Sargent MA, et al. An acute immune response underlies the benefit of cardiac stem cell therapy. Nature 2020;577:405-9.

36. Epstein JA, Rosenthal N, Feldman AM. Teasing the immune system to repair the heart. N Engl J Med 2020;382:1660-2.

37. Vagnozzi RJ, Kasam RK, Sargent MA, Molkentin JD. Cardiac cell therapy fails to rejuvenate the chronically scarred rodent heart. Circulation 2021;144:328-31.

38. Cardiovascular Research. Cardiovascular research discoveries. Available from: https://academic.oup.com/cardiovascres/pages/webinars [Last accessed on 20 Apr 2022] Eshenhagen T, Vagnozzi R. Cardiovascular Research Discoveries. Available from: https://www.youtube.com/watch?v=yEEwx5xIqHs [Last accessed on 20 Apr 2022].

39. Cooke JP. Inflammation and its role in regeneration and repair. Circ Res 2019;124:1166-8.

40. Finan A, Richard S. Stimulating endogenous cardiac repair. Front Cell Dev Biol 2015;3:57.